PLx Pharma (PLXP) Issues Earnings Results, Meets Estimates

PLx Pharma (NASDAQ:PLXP) issued its quarterly earnings data on Friday. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.39), MarketWatch Earnings reports. PLx Pharma had a negative return on equity of 169.28% and a negative net margin of 12.57%. The business had revenue of $0.22 million during the quarter.

PLXP traded down $0.04 during trading on Friday, reaching $3.85. The stock had a trading volume of 1,360 shares, compared to its average volume of 4,015. The company has a market capitalization of $32.32 million, a price-to-earnings ratio of -1.97 and a beta of 1.68. The company has a debt-to-equity ratio of 0.93, a current ratio of 9.15 and a quick ratio of 9.15. PLx Pharma has a 1-year low of $3.05 and a 1-year high of $7.60.

Separately, ValuEngine downgraded PLx Pharma from a “hold” rating to a “sell” rating in a research report on Wednesday, September 12th.

TRADEMARK VIOLATION WARNING: “PLx Pharma (PLXP) Issues Earnings Results, Meets Estimates” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this piece of content can be viewed at

About PLx Pharma

PLx Pharma Inc, a late-stage specialty pharmaceutical company, focuses on developing non-steroidal anti-inflammatory drugs (NSAIDs) and other analgesics. The company's lead product candidates are Aspertec 81 mg and 325 mg, which are novel formulations of aspirin that use the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention.

Recommended Story: What are the risks of holding treasury bonds?

Earnings History for PLx Pharma (NASDAQ:PLXP)

Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with's FREE daily email newsletter.

Leave a Reply